Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of ThisCART22 in Relapsed/Refractory B-Cell Malignancies
NCT04601181Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ThisCART22 cells in B-cell malignancy, sponsored by Fundamenta Therapeutics Inc. Primary endpoints: Incidence of Adverse Events or Serious Adverse Events of Grade >= 3 at 12 weeks and Overall Response Rate at 12 weeks. Status: unknown.
02
Drugs
ThisCART22 cells
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT04601181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601181.